agilon health, inc.

agilon health, inc.(AGL)股票分析

$87.400

+1.530 (+1.75%)收盘时

Loading chart…
最高
87.400
开盘
84.080
成交量加权均价
86.29
成交量
145.32K
市值
2.71B
最低
84.080
成交额
12.54M
企业价值/息税折旧摊销前利润(TTM)
12.48

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.

AI 分析 of agilon health, inc. (AGL)

买入

Agilon Health Inc. is a good buy right now due to its recent strong earnings performance, with Q2 2026 revenue of $1.49 billion exceeding expectations and adjusted EPS of $2.15 far surpassing the estimate of $0.27. Additionally, the stock has a significant upside potential with an analyst price target of $125, representing a potential increase of 51.5% from the current price of $82.39. However, a key risk is the negative net income reported in recent quarters, with a net income of $17.96 million in Q2 2026, which indicates ongoing challenges in profitability.

估值指标

agilon health, inc.(AGL)当前预期市盈率为 178.57,5 年平均预期市盈率为 26.95。

预期市盈率

合理
5 年均值 P/E
26.95
当前P/E
178.57
高估
320.00
低估
-266.11

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
146.56
当前EV/EBITDA
12.48
高估
588.29
低估
-295.17

预期市销率

合理
5 年均值 P/S
1.17
当前P/S
0.23
高估
2.40
低估
-0.06

Alphio AI 对 AGL 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%AGL

$3.37

情景价格

基

基准

基准 · 50%AGL

$3.18

情景价格

悲

悲观

悲观 · 25%AGL

$2.51

情景价格

持有 AGL 的大户

I

IOOF Investment Management Limited

+ 持有AGL

-1.71%

3个月收益率

D

Durable Capital Partners, LP

+ 持有AGL

-6.36%

3个月收益率

R

Rock Springs Capital Management LP

+ 持有AGL

-11.63%

3个月收益率

事件时间线

2026-09-30 (ET)

09:30:00

Agilon Health Expands Partnership with The Jackson Clinic

2026-09-23 (ET)

09:30:00

Agilon Health Expands Partnership with Springfield Clinic

2026-09-10 (ET)

09:30:00

Agilon Health Expands Partnership with Family Practice Center

2026-08-05 (ET)

17:00:00

Sees Q3 Adjusted EBITDA at -$5M

17:00:00

agilon health Q2 Revenue $1.49B, Exceeds Expectations

资讯

AGL 常见问题 —— 由 Alphio AI 解答

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Agilon Health Inc. is a good buy right now due to its recent strong earnings performance, with Q2 2026 revenue of $1.49 billion exceeding expectations and adjusted EPS of $2.15 far surpassing the estimate of $0.27. Additionally, the stock has a significant upside potential with an analyst price target of $125, representing a potential increase of 51.5% from the current price of $82.39. However, a key risk is the negative net income reported in recent quarters, with a net income of $17.96 million in Q2 2026, which indicates ongoing challenges in profitability.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易